The discovery of the S1-4-A09 antibody and its A80P derivative opens up a range of potential applications in the field of Ebola virus therapeutics. These antibodies could be further developed as components of novel combination therapies for the treatment of Ebola virus disease, potentially increasing treatment efficacy and patient outcomes. Additionally, their enhanced stability and manufacturing feasibility make them attractive candidates for large-scale production and distribution, particularly in resource-limited settings where outbreaks often occur. Furthermore, the antibodies' unique binding characteristics and synergistic effects with other antibodies suggest they may also have utility in prophylactic applications, such as post-exposure prophylaxis for individuals at high risk of Ebola virus exposure. Overall, the discovery of S1-4-A09 and its derivative has the potential to significantly impact the field of Ebola virus therapeutics and improve the global response to Ebola virus outbreaks